# A Phase 1 Safety and Immunogenicity Study of the Epitope Based DNA Vaccine (EP HIV-1090) in HIV-1 Infected Individuals Receiving Antiretroviral Therapy (ART)

> **NCT00532974** · PHASE1 · UNKNOWN · sponsor: **Epimmune** · enrollment: 32 (estimated)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** EP1090
- **BIOLOGICAL:** EP1090

## Key facts

- **NCT ID:** NCT00532974
- **Lead sponsor:** Epimmune
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-10
- **Primary completion:** —
- **Final completion:** 2008-04
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2007-12-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00532974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00532974, "A Phase 1 Safety and Immunogenicity Study of the Epitope Based DNA Vaccine (EP HIV-1090) in HIV-1 Infected Individuals Receiving Antiretroviral Therapy (ART)". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00532974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*